Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xaliproden in mild-to-moderate Alzheimer's disease
NCT00103649Phase 3Completed
- Sponsor
- Sanofi
- Start
- Nov 2003
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of xaliproden in Alzheimer's disease (AD), sponsored by Sanofi. Started Nov 2003; status: completed.
02
Drugs
xaliproden
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00103649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00103649.